Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients

被引:44
作者
Rhodes, M
Lautz, T
Kavanaugh-Mchugh, A
Manes, B
Calder, C
Koyama, T
Liske, M
Parra, D
Frangoul, H
机构
[1] Vanderbilt Childrens Hosp, Pediat Stem Cell Transplant Program, Nashville, TN USA
[2] Vanderbilt Childrens Hosp, Dept Pediat Cardiol, Nashville, TN USA
[3] Vanderbilt Univ, Dept Biostat, Nashville, TN USA
关键词
effusion; tamponade; pediatric;
D O I
10.1038/sj.bmt.1705023
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Pericardial effusion and cardiac tamponade is a rarely reported complication following stem cell transplant (SCT). The incidence among pediatric SCT recipients is not well defined. To assess the frequency of clinically significant pericardial effusions, we retrospectively examined clinically significant cardiac effusions at our center. Between January of 1993 and August 2004, clinically significant pericardial effusions were identified in nine of 205 patients (4.4%). The median age at the time of transplant was 9 years (range 0.6-18 years) and seven received an allogeneic transplant. All nine had normal cardiac function prior to transplant. The effusion developed at a median of 30 days (range 18-210 days). All allogeneic recipients had acute or clinically extensive graft-versus-host disease (GVHD) at the time the effusion was diagnosed. Seven patients (78%) required pericardiocentesis or surgical creation of a pericardial window. No patient died as a complication of the effusion or the therapeutic procedures. Clinically significant pericardial effusions are more common than previously reported in pediatric SCT recipients. Acute and chronic GVHD is an associated factor.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 22 条
[1]  
ANGELUCCI E, 1994, BONE MARROW TRANSPL, V13, P827
[2]   SUDDEN CARDIAC-TAMPONADE AFTER CHEMOTHERAPY FOR MARROW TRANSPLANTATION IN THALASSEMIA [J].
ANGELUCCI, E ;
MARIOTTI, E ;
LUCARELLI, G ;
BARONCIANI, D ;
CESARONI, P ;
DURAZZI, SMT ;
GALIMBERTI, M ;
GIARDINI, C ;
MURETTO, P ;
POLCHI, P ;
SGARBI, E .
LANCET, 1992, 339 (8788) :287-289
[3]  
APPELBAUM FR, 1976, LANCET, V1, P58
[4]  
BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P173
[5]   Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors [J].
Brockstein, BE ;
Smiley, C ;
Al-Sadir, J ;
Williams, SF .
BONE MARROW TRANSPLANTATION, 2000, 25 (08) :885-894
[6]  
BUNKER CB, 1989, LANCET, V1, P435
[7]  
Cereda Manuela, 2003, Ital Heart J, V4, P60
[8]  
CHANDRARATNA PAN, 1991, CIRCULATION S1, V84, P303
[9]  
CROSSLEY RJ, 1984, SEMIN ONCOL, V11, P54
[10]   CARDIOTOXICITY ASSOCIATED WITH HIGH-DOSE CYCLOPHOSPHAMIDE THERAPY [J].
GOTTDIENER, JS ;
APPELBAUM, FR ;
FERRANS, VJ ;
DEISSEROTH, A ;
ZIEGLER, J .
ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (06) :758-763